岡山医学会Acta Medica Okayama0030-1558957-81983悪性腫瘍患者における細胞性免疫応答に関する研究 第2編 悪性リンパ腫患者における白血球遊走阻止試験について721729ENSeiyaTeraoThree different procedures of the leukocyte migration inhibition test(LMIT) were performed in order to study cell-mediated immunity in patients with malignant lymphoma. Using sonicated antigens from normal lymphocytes and lymphoma cells obtained by lymphnode biopsy, leukocytes from patients with malignant lymphoma showed a positive reaction exclusively against antigens obtained from malignant lymphoma cells. It was suggested that patients with malignant lymphoma had a cell-mediated immunity against the tumor-associated antigens. The migration index of LMIT using autochthonous antigen was significantly lower than that using allogeneic antigen. In LMITs using 3M KCI extracts of established lymphoid cell lines, it was suggested that there were both tumor-associated antigens and leukemia-lymphoma associated antigens in the extracts. The serum immuno-suppressive factor was positive in 40 of 50 patients' sera(80%) in LMITs. The suppressive ratio and immune complex levels of the sera from patients with extensive disease was significantly higher than that of patients with localized disease. Studies on cell-mediated immunity in patients with malignant tumor.No potential conflict of interest relevant to this article was reported.岡山医学会Acta Medica Okayama0030-1558957-81983悪性腫瘍患者における細胞性免疫応答に関する研究 第1編 原発性肺癌患者における白血球遊走阻止試験について711719ENSeiyaTeraoLeukocyte migration inhibition tests (LMIT) were performed in 46 patients with primary lung cancer. The three kinds of antigens were allogeneic 3 M KCl extracts of lung cancer tissues obtained from patients with adenocarcinoma, squamous cell carcinoma and small cell carcinoma. Nine of the 46 patients (19%) had positive LMITs using adenocarcinoma antigen, seven patients (15%) with squamous cell carcinoma antigen and eleven patients (24%) with samll cell carcinoma antigen. LMITs were all negative in 10 patients with benign lung disease, 10 patients with non-pulmonary cancer and 12 healthy volunteers. These findings suggested that some patients with lung cancer had cell-mediated immunity against a lung tumor-associated antigen not restricted to a given histologic type of lung cancer. Further study on the relationship between LMIT and the clinical stage of lung cancer revealed that the percentage of positive LMITs in patients with localized disease was higher than in patients with extensive disease.No potential conflict of interest relevant to this article was reported.